{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:14:37Z","timestamp":1791342877052,"version":"4.3.1"},"publisher-location":"Chichester, UK","reference-count":49,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd006986.pub2","type":"reference-entry","created":{"date-parts":[[2011,2,4]],"date-time":"2011-02-04T18:41:26Z","timestamp":1296844886000},"source":"Crossref","is-referenced-by-count":18,"title":["Acetylcholinesterase inhibitor treatment for myasthenia gravis"],"prefix":"10.1002","author":[{"given":"Man Mohan","family":"Mehndiratta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Kuntzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,2,16]]},"reference":[{"key":"10.1002\/14651858.CD006986.pub2-BIB1|cit1","first-page":"59","article-title":"Intra nasal neostigmine as add-on therapy in myasthenia gravis","volume":"243 Suppl","author":"Badrising","year":"1996","journal-title":"Journal of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD006986.pub2-BIB2|cit2","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s004150050059","article-title":"Myasthenia gravis: diagnosis and follow-up of\u00a0100 consecutive patients","volume":"244","author":"Beekman","year":"1997","journal-title":"Journal of Neurology"},{"issue":"9","key":"10.1002\/14651858.CD006986.pub2-BIB3|cit3","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1212\/01.wnl.0000183145.91579.74","article-title":"Nonresponsiveness to anticholinesterase agents in patients with MuSK-antibody-positive MG","volume":"65","author":"Hatanaka","year":"2005","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD006986.pub2-BIB4|cit4","first-page":"98","article-title":"Mestinon (pyridostigmine bromide) in myasthenia gravis","volume":"75","author":"Schwarz","journal-title":"Canadian Medical Association Journal"},{"key":"10.1002\/14651858.CD006986.pub2-BIB5|cit5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1620\/tjem.169.77","article-title":"Treatment of myasthenia gravis: a comparison of the natural course and current therapies","volume":"169","author":"Seto","year":"1993","journal-title":"Tohoku Journal of Experimental Medicine"},{"key":"10.1002\/14651858.CD006986.pub2-BIB6|cit6","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1749-6632.1998.tb11017.x","article-title":"\u00a0Late-onset myasthenia gravis. Follow-up of 113 patients diagnosed after age 60","volume":"841","author":"Slesak","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1002\/14651858.CD006986.pub2-BIB7|cit7","first-page":"256","article-title":"Myasthenia gravis in children: clinical study of 77 patients. [Chinese]","volume":"42","author":"Zhou","year":"2004","journal-title":"Zhonghua Erke Zazhi"},{"issue":"11","key":"10.1002\/14651858.CD006986.pub2-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1212\/01.WNL.0000163988.28892.79","article-title":"Quantitative myasthenia gravis score: Assessment of responsiveness and longitudinal validity","volume":"64","author":"Bedlack","year":"2005","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006986.pub2-BIB9|cit9","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.nmd.2006.05.006","article-title":"A systematic review of diagnostic studies in myasthenia gravis","volume":"16","author":"Benatar","year":"2006","journal-title":"Neuromuscular Disorders"},{"issue":"2","key":"10.1002\/14651858.CD006986.pub2-BIB10|cit10","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005081.pub2","article-title":"Medical and surgical treatment for ocular myasthenia","author":"Benatar","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"17","key":"10.1002\/14651858.CD006986.pub2-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1212\/01.wnl.0000327669.75695.38","article-title":"Treatment of ocular symptoms in myasthenia gravis","volume":"71","author":"Bhanushali","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006986.pub2-BIB12|cit12","first-page":"2843","article-title":"Myasthenia gravis: past, present, and future","volume":"116(11)","author":"Conti-Fine","journal-title":"Journal of Clinical Investigation"},{"issue":"8","key":"10.1002\/14651858.CD006986.pub2-BIB13|cit13","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/archneur.1986.00520080081029","article-title":"The office Tensilon test for ocular myasthenia gravis","volume":"43","author":"Daroff","journal-title":"Archives of Neurology"},{"issue":"12","key":"10.1002\/14651858.CD006986.pub2-BIB14|cit14","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1212\/01.WNL.0000098887.24618.A0","article-title":"Treatment of autoimmune myasthenia gravis","volume":"61","author":"Drachman","year":"2003","journal-title":"Neurology"},{"issue":"25","key":"10.1002\/14651858.CD006986.pub2-BIB15|cit15","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1056\/NEJM199406233302507","article-title":"Myasthenia gravis","volume":"330","author":"Drachman","journal-title":"The New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006986.pub2-BIB16|cit16","volume-title":"Meyler's Side Effects of Drugs","author":"Dukes","year":"2006"},{"issue":"12","key":"10.1002\/14651858.CD006986.pub2-BIB17|cit17","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1212\/WNL.23.12.1273","article-title":"Study of long-term anticholinesterase therapy. Effects on neuromuscular transmission and on motor end-plate fine structure","volume":"23","author":"Engel","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006986.pub2-BIB18|cit18","first-page":"1755","article-title":"Acquired autoimmune myasthenia gravis","volume-title":"In: Myology, Andrew G. Engel & Clara Franzini-Armstrong, (editors), 3rd edition","author":"Engel","year":"2004"},{"issue":"2","key":"10.1002\/14651858.CD006986.pub2-BIB19|cit19","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.nurt.2007.01.001","article-title":"The therapy of congenital myasthenic syndromes","volume":"4","author":"Engel","journal-title":"Neurotherapeutics"},{"issue":"4","key":"10.1002\/14651858.CD006986.pub2-BIB20|cit20","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002275","article-title":"Plasma exchange for myasthenia gravis","author":"Gajdos","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD006986.pub2-BIB21|cit21","article-title":"Intravenous immunoglobulin for myasthenia gravis","author":"Gajdos","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD006986.pub2-BIB22|cit22","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1540-8167.2007.00938.x","article-title":"Treatment of pyridostigmine-induced AV block with hyoscyamine in a patient with myasthenia gravis","volume":"19","author":"Gehi","journal-title":"Cardiovascular Electrophysiology"},{"key":"10.1002\/14651858.CD006986.pub2-BIB23|cit23","unstructured":"Jan Brozek Andrew Oxman Holger Sch\u00fcnemann GRADEpro 2008"},{"key":"10.1002\/14651858.CD006986.pub2-BIB24|cit24","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1749-6632.1981.tb33764.x","article-title":"The natural course of myasthenia gravis and effect of therapeutic measures","volume":"377","author":"Grob","year":"1981","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"4","key":"10.1002\/14651858.CD006986.pub2-BIB25|cit25","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005224.pub2","article-title":"Immunosuppressive agents for myasthenia gravis","author":"Hart","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006986.pub2-BIB26|cit26","unstructured":"Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions Chichester (UK) John Wiley & Sons"},{"key":"10.1002\/14651858.CD006986.pub2-BIB27|cit27","first-page":"16","article-title":"Myasthenia gravis: recommendations for clinical research standards","volume":"55(1)","author":"Jaretzki","journal-title":"Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology"},{"issue":"1","key":"10.1002\/14651858.CD006986.pub2-BIB28|cit28","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0022-510X(84)90050-9","article-title":"Anticholinesterase abuse in myasthenia gravis","volume":"64","author":"Munsat","journal-title":"Journal of the Neurological Sciences"},{"issue":"1","key":"10.1002\/14651858.CD006986.pub2-BIB29|cit29","first-page":"5","article-title":"The emerging diversity of neuromuscular junction disorders","volume":"26","author":"Newsom-Davis","journal-title":"Acta Myologica"},{"key":"10.1002\/14651858.CD006986.pub2-BIB30|cit30","first-page":"45","article-title":"Comparison of diagnostic tests in myasthenia gravis","volume":"19","author":"Nicholson","year":"1983","journal-title":"Clinical and Experimental Neurology"},{"key":"10.1002\/14651858.CD006986.pub2-BIB31|cit31","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/j.1749-6632.1981.tb33766.x","article-title":"Observations of the natural history of myasthenia gravis and the effect of thymectomy","volume":"377","author":"Oosterhuis","year":"1981","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1002\/14651858.CD006986.pub2-BIB32|cit32","first-page":"75","article-title":"Long-term effects of treatment in 374 patients with myasthenia gravis","volume":"25","author":"Oosterhuis","year":"1988","journal-title":"Monographs in Allergy"},{"key":"10.1002\/14651858.CD006986.pub2-BIB33|cit33","first-page":"265","article-title":"Rapid diagnostic test for myasthenia gravis: increased muscle strength, without fasciculations, after intravenous administration of edrophonium (tensilon) chloride","volume":"150(4)","author":"Osserman","journal-title":"Journal of the American Medical Association"},{"key":"10.1002\/14651858.CD006986.pub2-BIB34|cit34","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/mus.20935","article-title":"Electrophysiological signs and the prevalence of adverse effects of acetylcholinesterase inhibitors in patients with myasthenia gravis","volume":"37","author":"Punga","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1002\/14651858.CD006986.pub2-BIB35|cit35","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/mus.21319","article-title":"Acetylcholinesterase inhibitors in MG: to be or not to be","volume":"39","author":"Punga","year":"2009","journal-title":"Muscle & Nerve"},{"key":"10.1002\/14651858.CD006986.pub2-BIB36|cit36","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1212\/01.WNL.0000098887.24618.A0","article-title":"Treatment of autoimmune myasthenia gravis","volume":"61(12)","author":"Richman","year":"2003","journal-title":"Neurology"},{"issue":"7","key":"10.1002\/14651858.CD006986.pub2-BIB37|cit37","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/jnnp.43.7.644","article-title":"Controversies about the treatment of myasthenia gravis","volume":"43","author":"Rowland","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"key":"10.1002\/14651858.CD006986.pub2-BIB38|cit38","first-page":"1978","article-title":"Clinical aspects of MuSK antibody positive seronegative MG","volume":"60(12)","author":"Sanders","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD006986.pub2-BIB39|cit39","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002828.pub2","article-title":"Corticosteroids for myasthenia gravis","author":"Schneider-Gold","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006986.pub2-BIB40|cit40","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1212\/01.WNL.0000065882.63904.53","article-title":"Clinical aspects of MuSK antibody positive seronegative MG","volume":"60","author":"Shapira","year":"2003","journal-title":"Neurology"},{"issue":"9","key":"10.1002\/14651858.CD006986.pub2-BIB41|cit41","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.clineuro.2010.06.018","article-title":"Benefits from sustained-release pyridostigmine bromide in myasthenia gravis: results of a prospective multicenter open-label trial","volume":"112","author":"Sieb","year":"2010","journal-title":"Clinical Neurology and Neurosurgery"},{"key":"10.1002\/14651858.CD006986.pub2-BIB42|cit42","first-page":"1","article-title":"Myasthenia gravis. An analysis of 295 cases","volume":"42 Suppl 23","author":"Simpson","year":"1966","journal-title":"Acta Neurologica Scandinavica"},{"key":"10.1002\/14651858.CD006986.pub2-BIB43|cit43","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1468-1331.2006.01476.x","article-title":"Guidelines for the treatment of autoimmune neuromuscular transmission disorders","volume":"13(7)","author":"Skeie","year":"2006","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD006986.pub2-BIB44|cit44","first-page":"161","article-title":"Chapter 8: Anticholinesterase agents","volume-title":"The Pharmacological Basis of Therapeutics","author":"Taylor","year":"1996"},{"key":"10.1002\/14651858.CD006986.pub2-BIB45|cit45","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1136\/jnnp.48.12.1246","article-title":"Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays","volume":"48(12)","author":"Vincent","year":"1985","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"key":"10.1002\/14651858.CD006986.pub2-BIB46|cit46","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/S0140-6736(00)05186-2","article-title":"Myasthenia gravis","volume":"357(9274)","author":"Vincent","year":"2001","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD006986.pub2-BIB47|cit47","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1474-4422(03)00306-5","article-title":"Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets","volume":"2(2)","author":"Vincent","year":"2003","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD006986.pub2-BIB48|cit48","first-page":"1198","article-title":"Treatment of myasthenia gravis with physostigmine","volume":"2","author":"Walker","year":"1934","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD006986.pub2-BIB49|cit49","series-title":"Procedings of the Royal Society of Medicine","first-page":"759","author":"Walker","year":"1935"}],"updated-by":[{"DOI":"10.1002\/14651858.cd006986.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2014,10,13]],"date-time":"2014-10-13T00:00:00Z","timestamp":1413158400000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD006986.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T22:06:04Z","timestamp":1628546764000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD006986.pub2"}},"subtitle":[],"editor":[{"given":"Man Mohan","family":"Mehndiratta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,2,16]]},"references-count":49,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006986.pub2","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD006986.pub3","asserted-by":"object"}]},"subject":[],"published":{"date-parts":[[2011,2,16]]}}}